A COVID-19 vaccine may be available for some people before Christmas, Kate Bingham, the chair of the UK government’s vaccine taskforce said in an interview. An early 2021 launch is more likely, she added.
Bingham wrote in medical journal The Lancet on Tuesday, “The first phase III efficacy data from the leading vaccine candidates are due by the end of 2020, subject to accruing sufficient rates of infection within the clinical trial cohorts to show the vaccines’ efficacy. The primary endpoint is to show that the vaccine can protect against SARS-CoV-2 infection and reduce symptom burden.”
Two phase III efficacy clinical trials are now underway in the UK — the Oxford AstraZeneca adenovirus-vectored vaccine and Novavax’s protein-adjuvant vaccine
ALSO READ| Covid-19 vaccine to be available by end of this year Oxford on verge of one says UK PM Boris Johnson
“If the first two vaccines, or either of them, show that they are both safe and effective, I think there is a possibility that vaccine roll out will start this side of Christmas, but otherwise I think it’s more realistic to expect it to be early next year,” Kate Bingham said on BBC television.
Earlier she mentioned that the first-generation of vaccines are prepared to fight the COVID-19 infection but may not be perfect and may not work for everyone.
“The first generation of vaccines is likely to be imperfect, and we should be prepared that they might not prevent infection but rather reduce symptoms, and, even then, might not work for everyone or for long,” she said.
AstraZeneca, the British pharma giant earlier said the trials of its coronavirus vaccine forged with Oxford University had shown “encouraging” responses among elderly, as well as younger participants.
She mentioned in the journal, the UK is committed to ensuring that everyone who is at risk of SARS-CoV-2 infection, anywhere in the world, has an access to a safe and effective vaccine.
The UK vaccine taskforce working towards the access to six vaccines (from more than 240 vaccines in development) across four different formats: adenoviral vectors, mRNA, adjuvanted proteins, and whole inactivated viral vaccines, which are promising in different ways.
COVID-19 vaccine still possible in 2020, Pfizer says:
Albert Bourla, Pfizer’s chief executive expressed optimism over the prospect of providing a coronavirus vaccine in 2020. “We have reached the last mile here,” Bourla said.
He further mentioned that the drug companies could supply about 40 million doses in the United States in 2020 if clinical testing proceeds as expected and regulators approve a vaccine. The company still had not reached any benchmark in assessing vaccine efficacy said Bourla.
He said it is the company’s expectation to file for emergency use authorization for its COVID-19 vaccine in the third week of November, roughly in line with earlier timetables.